NEW ORLEANS, LA—A novel transcatheter intracardiac shunt device appears to provide sustained clinical benefit at 1 year in heart failure patients with preserved or only mildly reduced ejection ...

Please provide your email address to receive an email when new articles are posted on . Physiologic aqueous outflow pathways include the conventional outflow pathway and the uveoscleral outflow.

A study of an investigational interatrial shunt for treating high-risk heart failure patients with reduced and preserved ejection fraction suggests the device has a high degree of safety and efficacy, ...

The US Food and Drug Administration (FDA) is warning healthcare providers about potential hazards from interactions between implanted programmable cerebrospinal fluid (CSF) shunts and hearing implants ...

The Interatrial shunt is intended for insignificantly obtrusive delivery to the heart using trans catheter systems. The dime-sized gadget is embedded into the septal wall between the atrial chambers, ...

The first implantation of a new device called interatrial shunt device (IASD) is a success. This device is developed by Corvia Medical. The device is a non-surgical device that provides continuous ...

ATLANTA, GA — Despite promise for improving heart failure (HF) in pilot studies, an interatrial shunt (IAS) device did not meet the primary composite efficacy endpoint in a pivotal trial, a result ...

NEWARK, Del, Feb. 20, 2024 (GLOBE NEWSWIRE) -- According to Future Market Insights’ latest industry analysis, the Hydrocephalus Shunt Market size is estimated to be around US$ 546.09 million in 2024.